← 홈

고형암 (전체) · HER2

43개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 43개
ADCBiologicstaleGI Innovation, Inc.Phase 2

GI-102 (GI-102)

Advanced Solid Tumor; Metastatic Solid Tumor · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 3상태 RECRUITING
AntibodystaleMargaret Gatti-MaysPhase 2

Naxitamab (Naxitamab)

Anatomic Stage IV Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 2상태 RECRUITING
CGTBiologicstaleUTC Therapeutics Inc.Preclinical

Anti-HER2 CAR-T cells (Anti-HER2 CAR-T cells)

HER2-positive Advanced Malignant Solid Tumors · HER2

#HER2#CGT#Preclinical#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleNational University Hospital, S…Phase 2

trastuzumab (Herceptin, Chimeric receptor T-cells + Trastuzumab)

HER2+ Advanced Breast Cancer; Other Solid Tumors · HER2

#HER2#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
ADCBiologicstaleRemeGenPreclinical

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab vedotin + Sintilimab + Multimodality radiotherapy)

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
AntibodystaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Dose Escalation Doublet: Combination of NKTR-214 + nivolumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 64%임상시험 1상태 ACTIVE
AntibodystaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 64%임상시험 1상태 ACTIVE
AntibodystaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 64%임상시험 1상태 ACTIVE
CGTBiologicstaleSichuan UniversityPhase 1

Dual-targeting HER2 and PD-L1 CAR-T cells (Dual-targeting HER2 and PD-L1 CAR-T cells)

Peritoneal Carcinoma Metastatic; Pleural Effusion, Malignant · HER2

#HER2#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing BiotechPhase 2

EGFR/HER2 Dual-Target CAR-NK Cells (EGFR/HER2 Dual-Target CAR-NK Cells)

Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma; Biomarker-positive EGFR/HER2- Expressing HNSCC · HER2

#HER2#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
AntibodystaleTianjin Medical University Canc…Preclinical

Enituzumab injection+Abesili tablets+Anastrozole tablets (Enituzumab injection+Abesili tablets+Anastrozole tablets)

Advanced HR+ HER2 Negative Breast Carcinoma · HER2

#HER2#Antibody#Preclinical#항체#면역항체+3
임상시험 1상태 ACTIVE
CGTBiologicstalesu haichuanPreclinical

HER2-E-CART cells (HER2-E-CART cells)

Solid Tumor · HER2

#HER2#CGT#Preclinical#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
ADCBiologicstaleAcademic and Community Cancer R…Phase 2

Multi-epitope HER2 Peptide Vaccine TPIV100 (Multi-epitope HER2 Peptide Vaccine TPIV100)

Breast Adenocarcinoma; Stage II Breast Cancer AJCC v6 and v7 · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 ACTIVE
ADCBiologicstaleGilead SciencesPreclinical

ADC (Non-Investigational Antibody-Drug Conjugates, Non-Investigational Antibody-Drug Conjugates (ADC))

HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma · HER2

#HER2#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING
ADCBiologicstaleZhengda Tianqing Pharmaceutical…Phase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48+AK105+cisplatin)

Advanced Gastric Carcinoma; HER2-positive Gastric Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 ACTIVE
AntibodystaleJiangsu HengRui Medicine Co., L…Phase 3

Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan (Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan)

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 64%임상시험 1상태 ACTIVE
AntibodystaleXencor, Inc.Phase 1

XmAb®23104 (XmAb®23104)

Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma · HER2

#HER2#Antibody#Phase1#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 1

ipilimumab (Yervoy®, Yervoy® (ipilimumab))

Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma · HER2

#HER2#Antibody#Phase1#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleHoffmann-La RochePhase 2

trastuzumab (Herceptin, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b)

Advanced Solid Tumors; HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING

2 / 3 페이지

← 이전다음 →